Replies to post #31151 on Inovio Pharmaceuticals Inc (INO)

[Stockman1010101]

Inovio phase 1 test data results were vague and not that impressive. I hope phase 2/3 are much more impressive with greater detail on how well the vaccine works. For this reason I expect the stock to revisit the $15 level. Holding with powder for this stock level. GLTA.